Rivaroxaban-balances bleeding risk in chronic coronary syndrome - Video

Published On 2022-09-06T10:00:15+05:30 | Updated On 6 Sept 2022 4:44 PM IST

Overview

Globally, the prevalence of chronic coronary syndrome (CCS) increases with age. In India, there is a rapidly growing burden of coronary artery disease (CAD), which has become the leading cause of morbidity and mortality. JAPI reports a review article, about Rivaroxaban a new drug that is effective in managing bleeding risk and ischemic events in Chronic coronary syndrome.

Despite recommended medical therapy, patients with chronic coronary syndrome are still at risk of ischemic events. Currently, dual antiplatelet therapy (DAPT) is recommended in the form of aspirin and low dose rivaroxaban in patients with stable coronary artery disease and/or peripheral artery disease (PAD).

Rivaroxaban has shown a low risk of drug-drug interaction, and it does not require regular monitoring for coagulation if given at fixed doses; owing to its predictable pharmacokinetics and pharmacodynamics properties. When the tablet is orally taken, it is quickly absorbed, and the maximum plasma concentration is achieved in 2–4 hours.

A low dose of rivaroxaban in combination with aspirin is a promising approach; however, for patients who might benefit the most, it still remains a challenge. Clinical trial data on this new drug was certainly very encouraging, with evidence from the COMPASS trial which was previously discussed.

To review it, the subgroups of COMPASS trials suggested that the addition of rivaroxaban to aspirin was associated with a significantly lower risk of ischemic events, mortality, and tolerable bleeding profile in patients with chronic coronary syndrome and high-risk factors.

Thus, this combination is cost-effective and generally well tolerated in patients with coronary artery disease and peripheral artery disease, as well as patients with chronic coronary syndrome and multimorbidity or high-risk populations.

Reference: Adik-Pathak L, Shirodkar S, Gupta A. Rivaroxaban, a New Molecule with Potential to Balance Bleeding Risk and Ischemic Events in Patients with Chronic Coronary Syndrome. J Assoc Physicians India 2022;70(8):84–88.

Speakers

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751